Qing-Hua Ke

Adjuvant anti-TIGIT plus anti-PD-1 in melanoma: A necessary failure that clarifies the path forward

The phase 3 KEYVIBE-010 trial investigated adjuvant vibostolimab (anti-TIGIT) plus pembrolizumab versus pembrolizumab alone in resected stage IIB–IV melanoma. At the first interim analysis, the combination met futility criteria, with a recurrence-free survival hazard ratio of 1.2...

H&E to recurrence score: A step forward, but not yet a substitute for genomic testing

Shamai and colleagues developed a multimodal deep-learning model that predicts Oncotype DX recurrence scores from routine H&E slides and clinicopathological variables in hormone receptor‑positive, HER2‑negative early breast cancer. Validated across the TAILORx trial and six exter...